Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

PRIMARY OBJECTIVES: I. To determine 6-month freedom from treatment failure for second-line therapy for acute graft versus host disease (aGVHD). II. To show that extracorporeal photopheresis (ECP) is associated with a superior 6 month (m) freedom from treatment failure (FFTF) as compared to other treatment modalities for second line therapy for aGVHD. III. To describe health care burden in patients receiving second line therapy for acute GVHD. IV. Quality of life measurement using Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) in patients receiving second line therapy for aGVHD. OUTLINE: Study data are collected and managed using Research Electronic Data Capture (REDCap) tools at baseline and on days 5, 28, and 56. After completion of study, patients are followed up at 6 months, and 1 and 2 years.